Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate-Reference-Cited by-同舟云学术

Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate

Published:2006-03-15 Issue:6 Volume:12 Page:1743-1749
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Wardelmann Eva,Merkelbach-Bruse Sabine,Pauls Katharina,Thomas Nadja,Schildhaus Hans-Ulrich,Heinicke Thomas,Speidel Nicola,Pietsch Torsten,Buettner Reinhard,Pink Daniel,Reichardt Peter,Hohenberger Peter

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 324 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance;Cancers;2024-09-07

2. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial;The Lancet Oncology;2024-09

3. Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors;BJC Reports;2024-07-25

4. Multi-omics reveals AKR1B1-regulated galactose metabolic as a driver of gastrointestinal stromal tumor progression;2024-05-21

5. Monitoring advanced gastrointestinal stromal tumor with circulating tumor DNA;Current Opinion in Oncology;2024-04-19